When you look matters: The effect of assessment schedule on progression-free survival

Journal of the National Cancer Institute

Volumn 99, Issue 6, 2007, Pages 428-432

  Panageas, Katherine S ^a   Ben Porat, Leah ^a   Dickler, Maura N ^a   Chapman, Paul B ^a   Schrag, Deborah ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONSENSUS DEVELOPMENT; DISEASE COURSE; DISEASE FREE SURVIVAL; EMBASE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MEDLINE; METASTASIS; NOTE; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT RESPONSE; ARTICLE; BREAST TUMOR; FEMALE; HEALTH SURVEY; METHODOLOGY; MORTALITY; NEOPLASM; NONPARAMETRIC TEST; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASMS; POPULATION SURVEILLANCE; QUINAZOLINES; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 34047254691     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk091     Document Type: Note

References (10)

1. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
3. Dickler M, Rugo H, Caravelli J, Brogi E, Sachs D, Panageas K, et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2004;22:127S.
4. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
5. Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998;17:219-38.
6. Peto R. Experimental survival curves for interval-censored data. Appl Stat 1973;22:86-91.
7. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976;38: 290-5.
8. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics 1992;48:951-9.
9. Groeneboom P, Wellner JA. Information bounds and nonparametric maximum likelihood estimation. New York (NY): Birkhauser; 1992.
10. SAS Institute Inc. ICE, macro to compute nonparametric survival curves for interval censored data. Jul 13, 1993 [cited 2005 January 27]. Available at: http://ftp.sas.com/techsup/download/stat/ice.html. [Last accessed: January 27, 2005.]